EraCal aims to raise CHF 15m Series A in 2021: the advisor

EraCal, a Swiss biotech developing an anti-obesity drug, aims to raise CHF 15m in a Series A round next year, according to Mergermarket who spoke with its CEO. The funds will help the company conduct GLP toxicology and Phase I studies of its lead anti-obesity asset, ERA-107. The Zurich-based company will open the round in 1Q 2021 and aims to close it by summer 2021. To notice that the company closed a CHF 6m seed round in October, with investors including RedalpineBernina BioInvest and the UZH Life Sciences Fund, a partnership between UZH Foundation and Novartis Venture Fund.

VISCHER is advising EraCal in this operation. 

EraCal aims to raise CHF 15m Series A in 2021: the advisor


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram